STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDCX
  4. [Form 3/A] Medicus Pharma Ltd. Amended Initial Statement of Beneficial Ownership

[Form 3/A] Medicus Pharma Ltd. Amended Initial Statement of Beneficial Ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3/A
Insider Smith Andrew Alasdair
Role Chief Operating Officer
Type Security Shares Price Value
holding Stock Option (right to buy) -- -- --
holding Common Shares, no par value ("Common Shares") -- -- --
Holdings After Transaction: Stock Option (right to buy) — 100,000 shares (Direct); Common Shares, no par value ("Common Shares") — 164 shares (Direct)
Footnotes (1)
  1. This amendment is being filed to include Common Shares that were inadvertently omitted from the Form 3 filed by the Reporting Person on July 3, 2025. The board of directors of Medicus Pharma Ltd. (the "Board") approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest annually in five equal installments beginning on June 30, 2026. All these options are now vested.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Smith Andrew Alasdair
(Last) (First) (Middle)
300 CONSHOHOCKEN STATE ROAD
SUITE 200
(Street)
W. CONSHOHOCKEN PA 19428
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
06/30/2025 		3. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
07/03/2025
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares, no par value ("Common Shares") 164(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (2) 06/30/2030 Common Shares 100,000 $2.6 D
Explanation of Responses:
1. This amendment is being filed to include Common Shares that were inadvertently omitted from the Form 3 filed by the Reporting Person on July 3, 2025.
2. The board of directors of Medicus Pharma Ltd. (the "Board") approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest annually in five equal installments beginning on June 30, 2026. All these options are now vested.
/s/ Andrew A. Smith 08/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR